Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT05840263
- Status
- Recruiting
Conditions
- Metastatic Colorectal Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Accepted
Interventions
- Qualitative interview — BEHAVIORALQualitative interviews will cover four main goals including: (1) key sources of distress in mCRC patients and partners; (2) perceptions of mindfulness, including benefits, definitions, and applications; (3) barriers and facilitators of participation (e.g. home-based and couple-based skills practice, enrollment); and (4) session format preferences, such as session length and frequency.
- Cognitive Interviews — BEHAVIORALThe objective of the cognitive interviews (60 minutes, led by the PI) is to ensure the comprehensibility and appropriateness of the drafted participant materials. Published guidelines note a sample size of 12 participants (6 mCRC couples) should be sufficient. Participants will be asked to read, review, and mark up the participant materials in order to identify sections that were difficult to understand. They will also be asked to test playing segments of the audio/video recordings to ensure ease of use. A semi-structured interview format will be used to elicit feedback, including a standard verbal survey assessing ease of reading the material, any difficulties experienced, and suggestions they have for improving the ease of material use. Information generated will be used to update materials as necessary.
Study Details
The overall objective of this study is to develop a novel couple-based mindfulness intervention aimed at reducing distress in patients with metastatic colorectal cancer (mCRC) and their partners.
Key Dates
- Start date
- May 31, 2023
- Status verified
- Feb 2026
- Primary completion
- Apr 30, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 48 participants (estimated)
Arms
- Arm: Metastatic Colorectal Cancer PatientsWe anticipate enrolling up to a total of 18 patients who have been diagnosed with metastatic colorectal cancer; 12 patients will participate in the qualitative interview, and 6 patients will participate in the cognitive interview.
- Arm: Metastatic Colorectal Cancer Patients PartnersWe anticipate enrolling up to a total of 18 partners of patients who have been diagnosed with metastatic colorectal cancer; 12 partners will participate in the qualitative interview, and 6 paartners will participate in the cognitive interview.
- Arm: CliniciansWe anticipate enrolling 12 clinicians (including physicians, nurse practitioners, physician assistants, mental health providers, other advanced practice clinicians) who treat patients with colorectal cancer at the University of Colorado to participate in qualitative interviews. We seek to enroll a variety of clinicians from advanced practiced clinical roles (physicians, nurse practitioners, and mental health providers) to capture diverse perspectives.
Primary Outcome Measure
Identify the needs of mCRC patients for intervention content [ Time Frame: During the one-time qualitative interview ]
Central Contacts
- Kaylee Ortega720-288-0714
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | Lauren Zimmaro, PhD (PRINCIPAL_INVESTIGATOR) Chris Lieu, MD (SUB_INVESTIGATOR) Jennifer Reese, MD (SUB_INVESTIGATOR) Jamie Studts, PhD (SUB_INVESTIGATOR) |
Find similar trials in Aurora, CO
By research site
Related Studies
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Artios Pharma Ltd · Birmingham, Alabama
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)PHASE1 · Recruiting · Hoffmann-La Roche · Birmingham, Alabama
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerPHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal CancerPHASE2 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin